CPD 2024
MEDICAL PROGRESS IN MOTION: PAVING THE WAY FOR THE FUTURE CPD 2024
PRESIDENTIAL WELCOME
Dear Esteemed Colleagues,
It is with great pleasure that I extend a warm welcome to all participants of The Society of Gynecologic Oncology of Canada (GOC) Continuing Professional Development (CPD) event May 2 & 3. As we gather for this occasion, I am honored to address you as the President of our esteemed society. These past years have been marked by dedication, collaboration, and a shared commitment to advancing the field of gynecologic oncology. I am immensely proud of the strides we have made together.
Alon Altman, GOC President
This CPD event promises to be a momentous occasion, filled with insightful discussions, cutting-edge presentations, and unparalleled networking opportunities. Our esteemed lineup of speakers and experts will provide invaluable insights into the latest advancements, fostering an environment of continuous learning and professional growth. As we collectively embark on this final leg of my presidency, I am filled with gratitude for the unwavering support and dedication of our members. It has been an incredible journey, and I am confident that the GOC will continue to flourish under new leadership. I encourage you all to actively engage in the sessions, share your experiences, and forge new connections that will undoubtedly contribute to the enhancement of our practice and, more importantly, the well-being of the patients we serve. May these two days be a celebration of our achievements, a testament to our shared commitment to excellence, and a catalyst for future advancements in gynecologic oncology. Thank you for being a part of the GOC community. I look forward to cherishing these moments with you and leaving a legacy as we continue our collective pursuit of excellence in women's health.
Warm regards,
Dr. Alon Altman President, The Society of Gynecologic Oncology of Canada
FELLOWS EDUCATION COURSE MAY 2ND, 2024 SOVEREIGN BALLROOM
12:30 - 13:30 11:30 - 12:00 13:30 - 14:30 14:30 - 15:00
Registration
Top 2023 Papers
Q & A Panel
Break
MOLECULAR BIOLOGY COURSE
Introduction Dr. Mark Carey
15:00 - 15:10
15:10 - 15:40
Biomarkers for prognosis and prediction of hormone responsiveness in low-grade serous ovarian carcinomas Dr. Nelson Wong ct DNA (HPV) as a prognostic and predictive biomarker in HPV-related Cervical Carcinoma Dr. Kathy Han MMR deficiency and other immune biomarkers Dr. Melica Brodeur
15:40 - 16:10
16:10 - 16:40
16:40 - 16:50
Wrap Up Discussion Dr. Mark Carey
17:00 - 18:00
Biology Course/Fellow Reception
AGENDA MAY 3RD, 2024 SOVEREIGN BALLROOM
7:15 - 7:45 7:45 - 8:10
Breakfast and Registration
Welcome and Announcements Dr. Alon Altman
Pembrolizumab or placebo with chemoradiotherapy Followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/ GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial Gabriel Levin 8:10 - 8:25 Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial l Katie McRae 8:25 - 8:40 Simple versus Radical Hysterectomy in Women with Low-Risk Cervical Cancer Cristina Mitric 8:40 - 8:55
9:00 - 9:45
Mirvetuximab and Antibody-Drug Conjugatest Dr. Katie Moore
9:45 - 10:15 10:15 - 10:45
Coffee and Exhibits
Evaluation of cost-effectiveness analysis of medications in Gynecologic Oncology Dr. Vanessa Carlson Understanding the Drug Funding Process and Health Technology Assessment Dr. Stephanie Snow
10:45 - 11:15
11:15 - 11:45
Drug Approval Process in Canada Dr. Marc Geirnaert
11:45 - 13:00 13:00 - 13:30
Lunch and Exhibits
Exploring Cultural Safety: Enhancing Indigenous Patient Care in Oncology Dr. Brent Jim
MAY 3RD, 2024 CONTINUED
13:30 - 14:00
Truth and reconciliation and relational accountabilities Dr. Mandy Buss
14:00 - 14:30
Providing Care to Indigenous Populations Dr. Brent Jim, Dr. Mandy Buss & Arrow BigSmoke. Indigenous Cancer Patient Navigation Arrow BigSmoke.
14:30 - 15:00
15:00 - 15:15 15:15- 15:45
Coffee and Exhibits
The Management of Menopause after Gynecologic Cancers Dr. Michelle Jacobson Hormones for treatment of cancer Dr. Sarah Kean
15:45 - 16:15
16:15 - 16:45
Fertility Preservation Options for Patients Diagnosed with Gynecologic Malignancies Dr. Miguel Russo
16:45 - 17:00
Announcements and Adjournment Dr. Alon Altman
17:00 - 18:00
Unwind and Recharge
18:00 - 19:00 19:00 - 23:00
Cocktail Reception
Dinner & Dance
LET’S PARTY! GOC’s 24th CPD Celebration
MEETING ANNUAL GENERAL
EDMONTON, AB
June 13 - 15, 2024
Register today!
INNOVATIONS IN MEDICINE: A PATH TO PROGRESS
June 14, 2024 at the Annual General Meeting
Where Members Showcase their Work! Publication Corner
Submission by Gabriel Levin Pembrolizumab or placebo with chemoradiotherapy Followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/ GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial
Submission by Katie McRae Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial
Submission by Cristina Mitric Simple versus Radical Hysterectomy in Women with Low-Risk Cervical Cancer
THANK YOU
PLATINUM SPONSORS
BRONZE SPONSORS
Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 Page 10 Page 11 Page 12Made with FlippingBook - PDF hosting